Immediate effects of systemic administration of normal and high O


Journal

BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061

Informations de publication

Date de publication:
06 2020
Historique:
received: 15 08 2019
revised: 10 12 2019
accepted: 30 12 2019
entrez: 13 6 2020
pubmed: 13 6 2020
medline: 11 6 2021
Statut: ppublish

Résumé

Haemoglobin vesicles (HbVs) are red blood cell (RBC) substitutes with a phospholipid bilayer membrane and a polyethylene modified surface (diameter=250 nm; P Left pneumonectomy was performed under mechanical ventilation on rats, followed by rapid exsanguination of ~30% of the total circulating blood volume. Rat RBCs shed in 5% human serum albumin (HSA) solution (rat RBC), HbV with high oxygen affinity in 5% albumin solution (low-P Systemic arterial blood pressure significantly decreased after exsanguination and increased after each infusion. In the HbV, low-P The oxygen-carrying ability of HbV was comparable to that of rat RBCs, even under impaired lung function after pneumonectomy. HbVs with high oxygen affinity may have more beneficial effects on oxygenation in pulmonary resection.

Sections du résumé

BACKGROUND
Haemoglobin vesicles (HbVs) are red blood cell (RBC) substitutes with a phospholipid bilayer membrane and a polyethylene modified surface (diameter=250 nm; P
METHODS
Left pneumonectomy was performed under mechanical ventilation on rats, followed by rapid exsanguination of ~30% of the total circulating blood volume. Rat RBCs shed in 5% human serum albumin (HSA) solution (rat RBC), HbV with high oxygen affinity in 5% albumin solution (low-P
RESULTS
Systemic arterial blood pressure significantly decreased after exsanguination and increased after each infusion. In the HbV, low-P
CONCLUSIONS
The oxygen-carrying ability of HbV was comparable to that of rat RBCs, even under impaired lung function after pneumonectomy. HbVs with high oxygen affinity may have more beneficial effects on oxygenation in pulmonary resection.

Identifiants

pubmed: 32527871
pii: 7/1/e000476
doi: 10.1136/bmjresp-2019-000476
pmc: PMC7292042
pii:
doi:

Substances chimiques

Blood Substitutes 0
Drug Carriers 0
Hemoglobins 0
Oxygen S88TT14065

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: HS is an inventor on patents related to the production and utilisation of haemoglobin vesicles.

Références

PLoS One. 2017 Jun 16;12(6):e0178724
pubmed: 28622333
Shock. 2009 May;31(5):507-14
pubmed: 18827742
Drug Metab Dispos. 2009 Jul;37(7):1456-63
pubmed: 19364827
Shock. 2012 Aug;38(2):153-8
pubmed: 22777109
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1702-9
pubmed: 12521933
Exp Hematol. 1980 May;8(5):584-92
pubmed: 7461058
Ann Thorac Surg. 2006 Feb;81(2):421-5; discussion 425-6
pubmed: 16427825
J Surg Res. 2009 Jan;151(1):48-54
pubmed: 18262559
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
Artif Cells Blood Substit Immobil Biotechnol. 2012 Feb;40(1-2):179-95
pubmed: 22288842
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1885-92
pubmed: 15563528
J Surg Res. 2009 Jun 15;154(2):336-44
pubmed: 19118846
Ann Thorac Surg. 2004 Sep;78(3):999-1002; discussion 1002-3
pubmed: 15337036
J Control Release. 2009 Jun 19;136(3):232-9
pubmed: 19245823
Thorax. 2006 Jul;61(7):597-603
pubmed: 16449262
ASAIO J. 1997 Jul-Aug;43(4):289-97
pubmed: 9242942
Crit Care Med. 2004 Feb;32(2):539-45
pubmed: 14758176
Bioconjug Chem. 2000 May-Jun;11(3):425-32
pubmed: 10821660
Methods Enzymol. 2009;465:363-84
pubmed: 19913177
Interact Cardiovasc Thorac Surg. 2008 Dec;7(6):1114-20
pubmed: 18713778
Am J Pathol. 2001 Sep;159(3):1079-88
pubmed: 11549600
Am J Physiol. 1999 Feb;276(2):H553-62
pubmed: 9950857
Transfusion. 2006 Mar;46(3):339-47
pubmed: 16533274
Biotechnol Prog. 1996 Jan-Feb;12(1):119-25
pubmed: 8845102

Auteurs

Ryo Hashimoto (R)

Division of General Thoracic Surgery, Department of Surgery, Tokai University-Isehara Campus, Isehara, Kanagawa, Japan.

Mitsutomo Kohno (M)

Division of General Thoracic Surgery, Department of Surgery, Tokai University-Isehara Campus, Isehara, Kanagawa, Japan kohno@tokai.ac.jp.

Kana Oiwa (K)

Division of General Thoracic Surgery, Department of Surgery, Tokai University-Isehara Campus, Isehara, Kanagawa, Japan.

Hiroto Onozawa (H)

Division of General Thoracic Surgery, Department of Surgery, Tokai University-Isehara Campus, Isehara, Kanagawa, Japan.

Masazumi Watanabe (M)

General Thoracic Surgery, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Tokyo, Japan.

Hirohisa Horinouchi (H)

General Thoracic Surgery, Saitama City Hospital, Saitama, Japan.

Hiromi Sakai (H)

Chemistry, Nara Medical University, Kashihara, Nara, Japan.

Koichi Kobayashi (K)

General Thoracic Surgery, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Tokyo, Japan.

Masayuki Iwazaki (M)

Division of General Thoracic Surgery, Department of Surgery, Tokai University-Isehara Campus, Isehara, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH